Trial Profile
A Phase 3, Double-Blind, Placebo-Controlled Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder (MDD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Cariprazine (Primary) ; Antidepressants
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 15 Feb 2023 Results(n=751) assessing efficacy and safety of cariprazine as adjunctive therapy for patients with major depressive disorder published in the American Journal of Psychiatry
- 12 Mar 2018 Status changed from active, no longer recruiting to completed.
- 05 Aug 2016 Primary endpoint (Montgomery-Asberg Depression Rating Scale) has not been met, according to an Allergan and Richter joint media release.